Piroxicam D3
(Synonyms: 吡罗昔康 D3; CP-16171 D3) 目录号 : GC61193
An internal standard for the quantification of piroxicam
Cas No.:942047-64-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Piroxicam-d3 is intended for use as an internal standard for the quantification of piroxicam by GC- or LC-MS. Piroxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties.1,2 It inhibits production of thromboxane B2 from arachidonic acid in HEL human erythroleukemic cells (IC50 = 0.45 ?M), which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F1α from arachidonic acid in Mono-Mac-6 cells (IC50 = 0.77 ?M), which endogenously express COX-2.2 Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC50 values of 240 and ~470 ?M, respectively. It reduces carrageenan-induced paw edema in rats when administered at doses of 1, 2.5, and 5 mg/kg.3 Formulations containing piroxicam have been used in the treatment of pain and inflammation associated with osteoarthritis and rheumatoid arthritis.
1.Pairet, M., van Ryn, J., Schierok, H., et al.Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomerInflamm. Res.47(6)270-276(1998) 2.Berg, J., Fellier, H., Christoph, T., et al.The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitroInflamm. Res.48(7)369-379(1999) 3.Buritova, J., Honore, P., Chapman, V., et al.Carrageenan oedema and spinal Fos-LI neurones are reduced by piroxicam in the ratNeuroreport6(10)1385-1388(1995)
| Cas No. | 942047-64-5 | SDF | |
| 别名 | 吡罗昔康 D3; CP-16171 D3 | ||
| Canonical SMILES | O=C(C1=C(O)C2=CC=CC=C2S(N1C([2H])([2H])[2H])(=O)=O)NC3=NC=CC=C3 | ||
| 分子式 | C15H10D3N3O4S | 分子量 | 334.36 |
| 溶解度 | DMSO : 50 mg/mL (149.54 mM; Need ultrasonic); H2O : 0.1 mg/mL (0.30 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9908 mL | 14.9539 mL | 29.9079 mL |
| 5 mM | 0.5982 mL | 2.9908 mL | 5.9816 mL |
| 10 mM | 0.2991 mL | 1.4954 mL | 2.9908 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。